Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease by Kristi Henjum et al.
RESEARCH Open Access
Cerebrospinal fluid soluble TREM2 in aging
and Alzheimer’s disease
Kristi Henjum1, Ina S. Almdahl2,3†, Vibeke Årskog1†, Lennart Minthon4, Oskar Hansson4, Tormod Fladby2,3
and Lars N. G. Nilsson1*
Abstract
Background: Alzheimer’s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful
biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to
late-onset AD and other neurodegenerative disorders. TREM2, a microglial receptor, is involved in innate immunity. A
cleaved fragment, soluble TREM2 (sTREM2), is present in the cerebrospinal fluid (CSF).
Methods: We developed and used a novel enzyme-linked immunosorbent assay to investigate the potential value of
CSF sTREM2 as an AD biomarker in two independent cohorts: an AD/mild cognitive impairment (MCI)/control cohort
(n = 100) and an AD/control cohort (n = 50).
Results: We found no significant difference in sTREM2 levels between groups of controls and patients with AD or MCI.
However, among all controls there was a positive correlation between sTREM2 and age (Spearman rho = 0.50; p < 0.001;
n = 75). In the AD/MCI/control cohort, CSF sTREM2 correlated positively with total Tau (T-tau) (Spearman rho 0.57;
p < 0.001; n = 50), phosphorylated Tau (P-tau) (Spearman rho 0.63; p < 0.001; n = 50) and amyloid-β1–42 (Aβ42)
(Spearman rho 0.35; p = 0.01; n = 50) in control subjects. Among controls with a CSF Aβ42 above a cut-off value
(700 pg/ml) in this cohort, the positive correlation between sTREM2 and Aβ42 was stronger (Spearman rho = 0.44;
p = 0.002; n = 46).
Conclusions: sTREM2 in CSF correlates with aging in controls, and with the neurodegenerative markers CSF T-tau/P-tau
among controls who are negative for AD CSF core biomarkers Aβ42, T-tau or P-tau.
Keywords: Aging, Alzheimer’s disease, Amyloid beta, Microgliosis, Mild cognitive impairment, Neuroinflammation,
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Background
Alzheimer’s disease (AD) is characterized by neurodegener-
ation in the presence of two neuropathological hallmarks,
extracellular amyloid-beta (Aβ) plaques and intracellular
neurofibrillary tangles (NFTs), in certain brain regions [1].
A definitive AD diagnosis relies on post-mortem histo-
logical confirmation, but imaging and analyses of cerebro-
spinal fluid (CSF) Aβ1–42 (Aβ42), total Tau (T-tau) and
phosphorylated Tau (P-tau) have transformed the field by
enabling early and reliable ante-mortem AD diagnosis.
These biomarkers are now included in the diagnostic
guidelines [2–4], but additional AD biomarkers are needed
to measure specific aspects and progression of this complex
disease. The AD brain is also affected by neuroinflamma-
tion, but the immune reactions involved are intricate and
their role in pathogenesis is partly unclear. Moreover bio-
markers of neuroinflammation are scarce [5]. Longitudinal
monitoring of astroglial or microglial activation with posi-
tron emission tomography (PET) imaging is used in re-
search but not established in clinical practice [6]. In CSF,
the potential value of many immune mediators as bio-
markers has been examined. A diagnostic or prognostic
value of different complement factors, acute-phase proteins,
cytokines or chemokines has been reported, but findings
have seldom been robust and reproducible [7]. YKL-40
might become a clinically useful marker of astrogliosis [8],
but markers of microgliosis will also be needed.
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Multiple genetic studies of late-onset AD point to a
causative role of innate immunity in the AD pathogenesis
[9–11]. Triggering receptor expressed on myeloid cells 2
(TREM2) is expressed abundantly by microglia [12, 13] and
TREM2 is a susceptibility gene for late-onset AD [14, 15].
Gene-expression analyses of late-onset AD post-mortem
brain also suggest that an immune-specific and microglia-
specific module around the TREM2 signalling adapter
DNAX activating protein 12 (DAP12) is involved in the
pathogenesis [16]. Moreover, TREM2 expression is elevated
with aging in human brain [12] and in the vicinity of amyl-
oid deposits in transgenic mouse models of AD [17].
TREM2 is a transmembrane innate immune receptor
undergoing ectodomain cleavage with extracellular release
of a soluble TREM2 (sTREM2) fragment which is detect-
able in CSF [18, 19]. A disintegrin and metalloproteinase
(ADAM)-10, a key enzyme for α-secretase cleavage of Aβ
precursor protein (AβPP), cleaves the TREM2 ectodomain
[18]. The remaining TREM2 C-terminal fragment is
digested by γ-secretase [20]. Since both genetic and patho-
logical studies link TREM2 to AD, sTREM2 might be a
useful biomarker of microglial activation or neurodegener-
ation. Improved abilities to monitor microglial function
and activity would also facilitate development of new
microglial-based therapeutics. In the present study, we
developed and validated an enzyme-linked immunosorbent
assay (ELISA) and explored whether sTREM2 could serve
as a diagnostic biomarker for AD or mild cognitive impair-
ment (MCI). Moreover, we examined whether sTREM2
levels correlated with the established AD CSF core bio-
markers Aβ42, T-tau or P-tau. We also analysed the effect
of normal aging, the most important risk factor of AD.
Methods
Clinical samples
The Swedish cohort was from the Memory Clinic of
Skåne University Hospital in Malmö, Sweden, and com-
prised 25 patients diagnosed with AD and 25 non-AD
individuals (controls). Patients diagnosed with AD met
the DSM-IIIR criteria for dementia [21] and the criteria
for probable AD, as defined by the National Institute of
Neurological and Communicative Disorders and Stroke
(NINCDS-ADRDA) [22]. All subjects were carefully
assessed and tested by medical doctors with extensive
experience in cognitive disorders. Their brains were ex-
amined with either magnetic resonance imaging (MRI)
or computed tomography (CT). Controls were clinically
followed up to ensure that the cognitive complaints at
baseline were not due to dementia or any other neuro-
degenerative disorder. The CSF samples of all patients
were collected as part of routine clinical investigation. In
conjunction with the investigation, oral informed con-
sent for future use of their banked CSF samples for re-
search purposes was obtained and documented in the
patients’ medical records. All patients were later instructed
to withdraw their permission if they changed their minds,
as advertised in the local press. The design of the study
was approved by the Local Ethics Committee of Lund
University in Sweden (permit 2010-401), and the study
procedure was conducted in accordance with the Declar-
ation of Helsinki.
The Norwegian cohort was from the Memory Clinic of
Akershus University Hospital in Lørenskog, Norway. The
cohort encompassed 50 patients diagnosed with either AD
or MCI, due to a pre-dementia stage of AD, and 50 cogni-
tively healthy controls. All patients were interviewed and
examined by a physician trained in diagnosing cognitive
disorders. They all underwent cognitive testing, either
cerebral MRI or CT, blood screening and standard lumbar
puncture as part of the clinical assessment. Patients met
either the National Institute on Aging–Alzheimer’s Asso-
ciation (NIA-AA) criteria for dementia due to AD [4] or
the high-likelihood NIA-AA criteria for MCI due to AD
[2] (29 patients and 21 patients, respectively). The controls
were either orthopaedic patients scheduled for elective
joint replacement surgery, spouses of patients attending
the Memory Clinic or individuals recruited through news-
paper advertisement. CSF was collected before administra-
tion of spinal anaesthesia in the orthopaedic patients. The
remaining controls underwent standard lumbar puncture.
Inclusion criteria for the controls were the absence of any
reported cognitive complaints and normal CSF Aβ42
concentrations according to the cut-off value set by the
laboratory (>550 pg/ml, modified from [23, 24]). All con-
trols were invited to undergo further assessments; 35
consented to cognitive testing and 32 to cerebral MRI.
Exclusion criteria for both AD patients and controls were:
any ongoing severe neurological, medical or psychiatric
co-morbidity or treatment with the potential to impair
cognitive functioning; systemic inflammatory disease or
infection based on clinical and laboratory assessment; and
use of immunosuppressant drugs. The three groups were
matched for age and gender. The Regional Committee for
Medical and Health Research Ethics, South East Norway,
approved the study (approval 1.2007.2511, 2011/1015 and
2013/150) and all participants gave written informed
consent. The study procedure was conducted in ac-
cordance with the Declaration of Helsinki. The demo-
graphics and clinical characteristics of both cohorts are
presented in Table 1.
The TREM2 [p. T66M] mutation prevents shedding
of TREM2, and CSF from a patient homozygous for
[p. T66M] is reported to be devoid of sTREM2 [18]. A
sample from such a patient was used to verify that the
ELISA signal was specific for sTREM2, and not partly due
to other components in the CSF matrix. Genomic DNA
from the [p. T66M] mutation carrier had been analysed
by exome sequencing of the entire genome [25].
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CSF collection and storage
Lumbar puncture was in general performed between
9 a.m. and 12 p.m., predominantly in the L3/L4 or L4/
L5 inter-space and without any reported serious adverse
effects. CSF was collected in polypropylene tubes, centri-
fuged and stored at −80 °C. The samples were subjected
to a maximum of two freeze–thaw cycles prior to deter-
mination of sTREM2 levels.
Cell cultures
The Chinese hamster ovary CHO-K1 and THP-1 cell lines
were purchased from American Type Culture Collection
Table 1 Characteristics of the Norwegian and Swedish cohorts
p value
Controls MCI AD Controls–MCI Controls–AD MCI–AD
Norwegian cohort n = 50 n = 21 n = 29
Gender
Women 25 12 13
Men 25 9 16
Age 66 (50–86) 67 (55–75) 68 (56–75)
MMSE 29 (29–30) 27 (26–29) 20 (17–24) * * *
CSF Aβ42 (pg/ml) 1010 (880–1188) 494 (356–531) 500 (386–553) * * 0.43
CSF T-tau (pg/ml) 307 (201–391) 628 (497–927) 772 (647–1143) * * 0.06
CSF P-tau (pg/ml) 51 (38–61) 75 (62–111) 72 (67–91) * * 1.00
ApoE genotype
E2/E3 8 – 1
E2/E4 – 1
E3/E3 35 5 5
E3/E4 6 8 12
E4/E4 – 8 10
Not known 1
CSF sTREM2 (ng/ml) 4.4 (3.0–5.7) 4.1 (2.4–5.9) 4.8 (3.5–7.1) 0.42 0.17 0.11




Age 62 (43–80) 79 (61–86)
MMSE 29 (28–30) 18 (13–22) *
CSF Aβ42 (pg/ml) 520 (469–597) 340 (265–430) *
CSF T-tau (pg/ml) 380 (233–480) 670 (490–895) *







CSF sTREM2 (ng/ml) 3.2 (2.8–5.0) 3.8 (2.6–5.6) 0.76
Descriptive statistics of gender, age, MMSE, ApoE genotype and CSF biomarker data of AD, MCI and control patients of the two cohorts
Data are presented as median (interquartile range), except age which is presented as median (minimum–maximum). Two-tailed p values obtained by Mann–Whitney U
test for group comparison
*p < 0.001
Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, ApoE apolipoprotein E, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination,
P-tau phosphorylated Tau, sTREM2 soluble triggering receptor expressed on myeloid cells 2, T-tau total Tau
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(ATCC, Rockville, MD, USA). CHO-K1 cells were cul-
tured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS) and 1 %
penicillin–streptomycin (Sigma, St. Louis, MO, USA). These
cells were transfected with a synthetic human TREM2-
DAP12 fusion gene that had been subcloned into the NheI
and BgIII sites and thus replaced copGFP in a pmaxGFP ex-
pression vector (Lonza, Basel, Switzerland). Transfections
were carried out using Lipofectamine LTX and Plus Reagent
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s recommendations. Conditioned cell culture
medium (conditioned medium) was collected 15 h after
transfection, centrifuged at 5200 × g for 15 min at 4 °C and
supplemented with Complete® protease inhibitor (Roche, Ba-
sel, Switzerland). The cells were washed with PBS and lysed
with 0.5 % (w/v) sodium dodecyl sulphate (SDS) (Sigma) in
PBS with Complete® and stored at –20 °C. The THP-1
monocyte cell line was cultured in RMPI with Glutamax
(Thermo-Scientific, Waltham, MA, USA) supplemented
with 10 % FBS and 1 % penicillin–streptomycin. For differ-
entiation, 0.1 μM phorbol 12-myristate 13-acetate (Sigma)
was added to the culture media. The conditioned medium
from the differentiated cells was collected after 48 h and
centrifuged at 5200 × g for 7 min. The supernatant was
supplemented with Complete®, stored at –80 °C and used
as an internal standard in the TREM2 ELISA.
TREM2 ELISA
Maxisorp plates (ThermoFischer, Waltham, MA, USA)
were coated by shaking them overnight at 4 °C with
capturing goat anti-human TREM2 antibody (R&D
Systems, Minneapolis, MN, USA) at a final concentra-
tion of 0.5 μg/ml in 50 mM carbonate–bicarbonate
buffer (pH 9.6). The plates were then blocked with 2 %
(w/v) bovine serum albumin in TTBS (20 mM Tris,
150 mM NaCl, pH 7.4 with 0.05 % (v/v) Tween-20) be-
fore sample incubation for 2 h at room temperature
(RT). Samples were diluted (CSF 16×, THP-1 condi-
tioned medium 16×, CHO-KI conditioned medium
50× and CHO-KI cell lysate 200×) in TTBS supple-
mented with 0.1 % (w/v) bovine serum albumin. The
plates were then incubated with HRP-conjugated detect-
ing mouse anti-human TREM2 antibody (Sino Biologics,
Beijing, China) at a final concentration of 0.4 μg/ml for
1 h at RT. TTBS was applied for washing between each
step. Finally TMB substrate (ANL produkter, Älvsjö,
Sweden) was added for signal detection and development
was stopped with 0.2 M H2SO4 (final concentration). The
plates were analysed with a SpectraMAX 190 spectropho-
tometer at 450 nm (Molecular Devices, Palo Alto, CA,
USA) and the data with SoftMax Pro software (Molecular
Devices). Recombinant TREM2 was used as standard
(Sino Biologics).
CSF freeze–thaw cycles
CSF samples (n = 2) were subjected to five rounds of
thawing and freezing. Briefly, samples of 15 μl were thawed
for 90 s in a water bath at room temperature, incubated for
15 min on ice and then transferred to –80 °C for 1 h.
T-tau, P-tau and Aβ42 ELISAs
CSF levels of T-tau, P-tau and Aβ42 were quantified
with commercially available ELISAs; Innotest® hTau Ag,
Innotest® phoshoTau (181P) [26, 27] and Innotest® β-
amyloid 1–42 [28] (Fujirebio Europe, Gent, Belgium).
Aβ1–38 (Aβ38), Aβ1–40 (Aβ40) and Aβ42 were ana-
lysed using a MSD Multi-Spot Assay System (Meso Scale
Discovery, Rockville, MA, USA) with 6E10 (BioLegend,
San Diego, CA, USA) as the detection antibody. The
Meso Scale Discovery analyses, which were applied to a
subset of patients in the Norwegian cohort, were carried
out according to the manufacturers’ procedures.
Statistical analyses
The statistical analyses were carried out with the Statis-
tical Package for Social Sciences (SPSS, version 22; IBM,
Armonk, NY, USA). Since the majority of the data were
skewed, correlations were assessed by non-parametric
Spearman rho and differences between groups by Mann–
Whitney U test. Standardized residuals in multiple linear
regression analyses gave no indication of violation of the
normal distribution. All p values are two-tailed, since all
hypotheses tested were two-sided. The significance level
was set at 0.05. Graphs were created with GraphPad Prism
(version 5.02; Graph Pad Software, La Jolla, CA, USA) or
Statistica software (version 10; Statsoft, Uppsala, Sweden).
Results
Sensitive and specific detection of human TREM2 with a
new sandwich ELISA
Human TREM2 cells and mock-transfected CHO-K1 cells
served as positive and negative control respectively for
ELISA validation. The ELISA easily detected TREM2 in
the cell lysate, as well as sTREM2 in the corresponding
conditioned medium from TREM2-transfected CHO-K1
cells. The signals from conditioned medium and cell lysate
of mock-transfected cells were at the level of the zero
standard. Cellular TREM2 and released sTREM2 were
thus detectable in complex biological samples without sig-
nificant cross-reactivity (Fig. 1). Intra-day and inter-day
variability was 6.7 ± 1.7 % and 5.7 ± 0.3 % respectively. The
readings did not depend on dilution of the CSF samples
(Additional file 1: Figure S1). The [p. T66M] mutation in
TREM2 markedly reduced cell surface transport and shed-
ding of TREM2 [18]. A CSF sample from a patient homo-
zygous for TREM2 [p. T66M] was used to further ensure
that the ELISA signal was solely due to sTREM2 in CSF.
This CSF sample gave an ELISA signal very close to the
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zero standard (Fig. 2b) and below the estimated ELISA de-
tection limit (62.5 pg/ml, Fig. 1b). Repeated freeze–thaw
cycles did not affect CSF sTREM2 levels in two random
CSF samples (Additional file 1: Figure S2).
CSF sTREM2 levels did not relate to clinical diagnosis or
degree of dementia
CSF sTREM2 was measured in samples from a Swed-
ish AD/control cohort and a Norwegian AD/MCI/
control cohort. The Norwegian cohort (n = 100) in-
cluded controls (n = 50), MCI patients (n = 21) and
AD patients (n = 29), and the Swedish cohort (n = 50)
included controls (n = 25) and AD patients (n = 25).
In line with the diagnosis, the AD patients had lower
Mini-Mental State Examination (MMSE) scores and
markedly reduced level of Aβ42 and elevated levels of T-
tau and P-tau in CSF as compared with controls in both
cohorts. The more pronounced separation in CSF Aβ42
levels between AD patients and controls in the Norwegian
cohort was predicted because this cohort was diagnosed
according to the revised NIA-AA criteria and controls
were excluded if CSF Aβ42 was below 550 pg/ml. The
groups in the Norwegian cohort were age matched, but
the age range was wider among the controls. In the
Swedish cohort, the controls were younger than the AD
patients. The gender distribution was comparable in the
control and MCI/AD groups of the Norwegian cohort. In
the Swedish cohort, there were more women in both the
control group and the AD group. The apolipoprotein E
(ApoE) genotypes were similarly distributed in both
Fig. 1 TREM2 ELISA. a Estimation of sTREM2 in conditioned medium and TREM2 levels in cell lysate of transiently transfected CHO-K1 cells. The
readings of the negative control samples, mock-transfected cell lysate and medium were equal to or slightly below the zero point in the standard
curve (OD ≈ 0.05; n = 2–4). b A representative standard curve in the ELISA assay (n = 2 at each concentration). Diluted CSF samples were read at
OD values in the range of 0.2–0.8. OD optical density, sTREM2 soluble triggering receptor expressed on myeloid cells 2
Fig. 2 CSF sTREM2 levels did not depend on clinical diagnosis in two independent cohorts. a In the Norwegian cohort, sTREM2 levels did not
significantly differ between controls (n = 50) and patients with Alzheimer’s disease (AD, n = 29) or mild cognitive impairment (MCI, n = 21). b The
outcome was the same in the Swedish cohort after analysing AD patients (n = 25) and controls (n = 25). CSF of a single patient homozygous for
the [p. T66M] mutation in TREM2 was used as a negative control in the ELISA assay. Smaller lines and larger lines represent interquartile range and
median, respectively. sTREM2 soluble triggering receptor expressed on myeloid cells 2
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cohorts, with more E3/E3 carriers in the control groups
and more E3/E4 and E4/E4 carriers in the disease groups
(Table 1).
There were no statistically significant differences in the
level of sTREM2 between the MCI, AD and control
groups in the Norwegian cohort (Fig. 2a and Table 1). The
lack of difference in CSF sTREM2 levels between AD pa-
tients and controls was confirmed in the Swedish cohort
(Fig. 2b and Table 1). All study groups displayed large
variability (interquartile range/(median × 2) ≈ 30–40 %)
but sTREM2 levels tended to be slightly elevated in the
AD group in both cohorts. When the cohorts were
merged to increase statistical power, there was still no dif-
ference in sTREM2 levels (p = 0.29) between AD patients
(n = 54) and controls (n = 75). The level of sTREM2 and
cognitive function (MMSE score) did not correlate even
when the AD groups were merged (Spearman rho = 0.14,
p = 0.33, n = 54). The lack of correlation between sTREM2
and MMSE score suggests that sTREM2 does not relate to
cognitive ability in AD.
CSF sTREM2 level correlated with age among controls
Next, because age is the main risk factor for AD, we
questioned whether CSF sTREM2 levels related to nor-
mal aging. The analysis therefore focused on the control
groups. As samples were assayed for sTREM2 in the
same laboratory, the two cohorts were merged for this
analysis. We found sTREM2 levels to increase with age
in the control group, as demonstrated by a significant
positive correlation (Spearman rho = 0.50; p < 0.001; n = 75;
Fig. 3). Interpolation of linear regression showed that
sTREM2 was ≈ 2.7 ng/ml at 50 years of age and ≈ 7.2 ng/
ml at 90 years of age (i.e. almost a threefold increase).
When cohorts were analysed separately, age and sTREM2
levels correlated significantly in the Norwegian cohort
(Spearman rho = 0.53; p < 0.001; n = 50), but the correl-
ation did not reach statistical significance in the Swedish
cohort (Spearman rho = 0.35; p = 0.08; n = 25). In the AD
groups we only found a positive correlation in the Swedish
cohort (Spearman rho = 0.46; p = 0.02; n = 25). The correl-
ation was weaker, but still positive, when the AD/MCI and
control groups from both cohorts were merged (Spearman
rho = 0.29; p < 0.001; n = 150; Table 2).
Relation between sTREM2 levels and AD CSF biomarker
levels, Aβ42 and P-tau/T-tau
AD is a complex and pathologically rather heterogeneous
disorder with substantial individual variability in the toler-
ance to neuropathological changes. We hypothesized that
the levels of TREM2 would reflect pathogenic processes
rather than clinical symptoms. Therefore, we examined
the relation between sTREM2 levels and the AD CSF bio-
markers Aβ42, T-tau and P-tau in the larger Norwegian
cohort in which the patients had been diagnosed accord-
ing to the NIA-AA criteria.
Aβ42 displayed a biphasic association pattern with
sTREM2, with a distinction between AD/MCI and con-
trols (Fig. 4a). There was a positive correlation between
sTREM2 and Aβ42 among all controls (Spearman rho =
0.35; p = 0.01; n = 50) but not among AD/MCI patients
(Table 3). Since Aβ42 and sTREM2 levels seemed to de-
pend on the diagnostic state, the material was stratified
and further examined. Controls with high Aβ42 (>700 pg/
ml) were further analysed, since those with a lower Aβ42
(<700 pg/ml) might already have amyloid pathology in the
brain. The cut-off value of 700 pg/ml was supported by
comparison between CSF Aβ42 levels and amyloid-PET
imaging in a separate group of Norwegian patients
(Additional file 1: Figure S3). The correlation was
stronger between CSF sTREM2 and Aβ42 among con-
trols with high Aβ42 (>700 pg/ml; Spearman rho = 0.44;
p = 0.002; n = 46; Fig. 5a and Table 3). CSF from many
controls was also assayed with Meso Scale Discovery
(MSD) for Aβ38, Aβ40 and Aβ42. In controls with high
Aβ42 (>700 pg/ml) there were significant positive
correlations between sTREM2 and Aβ38 (Spearman
rho = 0.51; p = 0.004; n = 31), between sTREM2 and
Aβ40 (Spearman rho = 0.53; p = 0.002; n = 31) and be-
tween sTREM2 and MSD estimates of Aβ42 (Spearman
rho = 0.40; p = 0.03; n = 31) (Additional file 1: Figure S4
and Table 3). Estimation of Aβ42 with two independent
techniques, Innotest® and MSD correlated strongly
(Spearman rho = 0.88; p < 0.001; n = 38). MSD estimates
of Aβ38 and Aβ40 in the same CSF sample also corre-
lated very well (Spearman rho = 0.96; p < 0.001; n = 38),
while correlations between MSD analyses of Aβ42 and
Aβ38 or Aβ40 in the same samples were somewhat weaker
(Spearman rho = 0.74; p < 0.001; n = 38) (Additional file 1:
Figure S5 and Table S1).
Fig. 3 CSF sTREM2 levels correlated with age in the control groups.
We found a significant positive correlation between age and sTREM2
in the control groups (Spearman rho = 0.50; p < 0.001; n = 75). The
regression line (dotted lines representing the 95 % confidence interval)
is based on merged data for both cohorts. sTREM2 soluble triggering
receptor expressed on myeloid cells 2
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CSF sTREM2 correlated positively with the neurodegen-
erative biomarkers T-tau (Spearman rho = 0.57; p < 0.001;
n = 50; Fig. 4b) and P-tau in the control group alone
(Spearman rho = 0.63; p < 0.001; n = 50; Fig. 4c) and also
when the control group was merged with the AD/MCI
group. In the AD/MCI groups, the neurodegenerative bio-
markers T-tau and P-tau did not relate to sTREM2. Simi-
lar plots and statistical calculations on data from the
Swedish cohort only resulted in a positive correlation be-
tween sTREM2 and P-tau in controls (Spearman rho =0.44;
p = 0.02; n = 25; Additional file 1: Figure S6 and Table 3).
sTREM2 levels correlated with age, Aβ42, Aβ40, Aβ38,
T-tau and P-tau among controls with low likelihood of
amyloid plaques, (Aβ42 > 700 pg/ml). Multiple linear re-
gression was therefore performed using age and Aβ42
(Fig. 5a), Aβ40 or Aβ38 as the explanatory variable for
sTREM2 levels. The level of sTREM2 associated posi-
tively with age (β1 = 0.12; p < 0.001) and Aβ42 (Innotest®)
(β2 = 0.003, p = 0.01, n = 46; Fig. 5b and Additional file 1:
Table S2). There were also significant positive associa-
tions between sTREM2 levels and age and MSD esti-
mates of Aβ38 (age β1 = 0.08, p = 0.02; Aβ38 β2 = 0.001,
p = 0.01, n = 31) and Aβ40 (age β1 = 0.07, p = 0.02; Aβ40
β2 = 0.0005, p = 0.01, n = 31; Additional file 1: Figure S7).
The corresponding analysis of sTREM2, age and the neu-
rodegenerative marker P-tau in the same cohort showed a
significant association with both explanatory variables: age
(β1 = 0.11, p = 0.003) and P-tau (β1 = 0.04, p = 0.02,
n = 46). The same multiple linear regression analysis of
the entire control group (Aβ42 Innotest®/T-tau/P-tau
(n = 50) or Aβ38/Aβ40/Aβ42 MSD (n = 32)) gave close to
identical results (Additional file 1: Table S2).
Discussion
In the current study a new ELISA was developed and
used to determine whether CSF sTREM2 related to AD,
AD neurochemical biomarkers and cognitively healthy
aging. A CSF sample from a patient homozygous for
TREM2 [p. T66M] and cultured cells with or without
TREM2 expression were used to validate the ELISA. We
examined whether sTREM2 levels related to diagnosis
and the AD CSF biomarkers Aβ42, T-tau and P-tau, in
two independent cohorts. While the Swedish cohort was
diagnosed according to the NINCDS-ARDRA criteria
[22], the Norwegian cohort was diagnosed according to
the 2011 NIA-AA criteria with CSF biomarkers [2, 4].
Naturally there was a more prominent difference in the
CSF AD biomarker signature between controls and AD/
MCI in the Norwegian cohort. The levels of sTREM2,
but not those of other biomarkers, were analysed in the
same laboratory with a robust assay with low inter-plate
and inter-day variability. We therefore considered it cor-
rect to pool the two cohorts when studying the relation
between sTREM2 and aging. In contrast, each cohort
Table 2 Correlation analyses of CSF sTREM2 in relation to age in the Norwegian and the Swedish cohorts
Correlations between sTREM2 and age























Age r = 0.34 r = 0.08 r = 0.03 r = 0.53 r = 0.56 r = 0.35 r = 0.46 r = 0.35 r = 0.29 r = 0.00 r = 0.50
p < 0.001 p = 0.69 p = 0.86 p < 0.001 p < 0.001 p = 0.01 p = 0.02 p = 0.08 p < 0.001 p = 1.00 p < 0.001
Correlation analyses of CSF sTREM2 in relation to age of AD, MCI and control patients of the two cohorts
Correlations are presented as Spearman rho (r) since most data not were normally distributed
Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, CSF cerebrospinal fluid, MCI mild cognitive impairment, sTREM2 soluble triggering receptor expressed on myeloid cells 2
Fig. 4 Relationship between sTREM2 levels and AD core biomarkers in CSF. The relationship between a sTREM2 and Aβ42, b sTREM2 and T-tau,
and c sTREM2 and P-tau in CSF among all subjects in the Norwegian cohort. Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, MCI mild cognitive
impairment, P-tau phosphorylated Tau, sTREM2 soluble triggering receptor expressed on myeloid cells 2, T-tau total Tau
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was examined separately for correlations involving Aβ42,
T-tau or P-tau since those data were generated in different
laboratories. We did not find any significant differences in
CSF the level of sTREM2 between AD patients, MCI pa-
tients and controls. However in the control group, the
level of sTREM2 correlated positively with aging.
The innate immune receptor TREM2 is predominantly
expressed in microglia and other myeloid cells [12, 29].
sTREM2 was first found in human CSF and conditioned
medium of dendritic cells [19]. It can be generated by se-
quential proteolysis of membrane-bound TREM2 [20], or
by an alternatively splicing pathway resulting in a tran-
script lacking the transmembrane domain [30]. sTREM2
levels in CSF could depend on the synthesis rate of
membrane-bound receptors in TREM2-expressing cells,
largely microglia and peripherally derived macrophages,
transport to the cell surface, shedding and degradation of
the sTREM2 fragment. TREM2 gene expression is regu-
lated by factors inducing myeloid cell differentiation [31].
TREM2 receptor recycling and shedding can also be regu-
lated by cytokines (e.g. interleukin-13) [32]. The turnover
of sTREM2 is unknown but other fragments generated by
shedding (e.g. soluble AβPP) have a short half-life (t1/2 ≈
4 h) in the mouse brain [33].
We investigated whether sTREM2 levels altered with age,
the most significant risk factor for AD and of importance
Table 3 Correlation analyses of CSF sTREM2 in relation to other AD CSF biomarkers in the Norwegian and Swedish cohorts
sTREM2 correlation
Norwegian cohort Swedish cohort
All (n = 100) AD (n = 29) MCI (n = 21) Control (n = 50) Aβ42 > 700 (n = 46) All (n = 50) AD (n = 25) Control (n = 25)
T-tau r = 0.28 r = 0.22 r = –0.06 r = 0.57 r = 0.63 r = 0.17 r = 0.05 r = 0.29
p = 0.005 p = 0.25 p = 0.81 p < 0.001 p < 0.001 p = 0.24 p = 0.82 p = 0.16
P-tau r = 0.33 r = –0.04 r = 0.27 r = 0.63 r = 0.69 r = 0.17 r = 0.00 r = 0.44
p = 0.001 p = 0.85 p = 0.24 p < 0.001 p < 0.001 p = 0.23 p = 0.99 p = 0.02
Aβ42 r = 0.04 r = –0.05 r = 0.07 r = 0.35 r = 0.44 r = 0.09 r = 0.35 r = 0.06
p = 0.67 p = 0.79 p = 0.77 p = 0.01 p = 0.002 p = 0.55 p = 0.09 p = 0.79
n = 32 n = 31
Aβ38 (MSD) r = 0.49 r = 0.51
p = 0.005 p = 0.004
Aβ40 (MSD) r = 0.51 r = 0.53
p = 0.003 p = 0.002
Aβ42 (MSD) r = 0.37 r = 0.40
p = 0.04 p = 0.03
Correlations between CSF sTREM2 levels and levels of T-tau, P-tau, Aβ42, Aβ38 MSD, Aβ40 MSD and Aβ42 MSD in AD, MCI and control patients of the two cohorts.
Correlations are presented as Spearman rho (r) since most data not were normally distributed
Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, CSF cerebrospinal fluid, MCI mild cognitive impairment, MSD Meso Scale Discovery, P-tau phosphorylated Tau,
sTREM2 soluble triggering receptor expressed on myeloid cells 2, T-tau total Tau
Fig. 5 Relationship between sTREM2 and Aβ42 and age in subjects with high CSF Aβ42. Control subjects with high CSF Aβ42 (Aβ42 > 700 ng/ml,
n = 46) were further analysed. a Relationship between sTREM2 and Aβ42 levels in CSF (Spearman rho = 0.44; p = 0.002; n = 46), the solid line
representing the linear regression line (dotted lines the 95 % confidence interval). b Surface plot showing the relation between age (z axis), Aβ42 (x
axis) and sTREM2 levels (y axis). Aβ42 amyloid beta 1–42, sTREM2 soluble triggering receptor expressed on myeloid cells 2
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to many neurodegenerative disorders. Aging is associated
with gliosis, increased microglial activity [5] and astrocyto-
sis in the brain [34]. In healthy controls we found a positive
correlation between age and sTREM2 levels with almost a
threefold increase from 50 to 90 years of age, suggesting
that sTREM2 levels are related to the normal aging process.
TREM2 mRNA was reported to increase by 50–100 % from
50 to 90 years of age with healthy human aging in several
brain regions [12]. In AD brain, the level of TREM2
protein was found to increase roughly 50 % in the tem-
poral cortex [35]. TREM2 mRNA expression was ele-
vated to a similar extent and related to Braak staging
[36]. Aging and AD thus enhanced TREM2 expression
to a quantitatively similar extent in human brain. We
found elevated CSF sTREM2 levels with aging but not
with AD. Therefore mechanisms other than TREM2 ex-
pression presumably play a significant role in elevated
sTREM2 levels with aging. We suggest that the age-
dependent increased CSF sTREM2 levels partly reflect
enhanced microglial TREM2 expression but also in-
duced shedding and/or reduced clearance. In the AD/
MCI groups, pathogenic processes including neurode-
generation might overshadow the effect of aging on
CSF sTREM2. Our data demonstrate the importance of
age-matched study groups.
sTREM2 has been suggested as a possible biomarker
of neuroinflammation, which is increasingly being recog-
nized as an early event in AD [37]. Therefore it is con-
ceivable that the level of CSF sTREM2 is increased in
early stages of AD, as it is in classical inflammatory con-
ditions like multiple sclerosis [19]. However, the AD risk
factor TREM2 [p. R47H] and frontotemporal dementia
mutations [25] are most probably loss of function,
resulting in reduced TREM2 cell surface localization and
shedding [18]. If such changes are relevant to sporadic
AD one would instead predict decreased CSF sTREM2.
Indeed, in a previous study CSF sTREM2 was reduced in
AD patients as compared with controls although intra-
group variability was extensive [18]. Our study also
showed large intra-group variability but sTREM2 levels
did not differ between AD and controls. Hence we could
not confirm reduced CSF sTREM2 in AD; instead, levels
of sTREM2 tended to be higher in AD than in controls
in both cohorts. We also included a group of MCI pa-
tients to see whether there were any differences in
sTREM2 relating to dementia. sTREM2 levels in MCI
did not differ from either the control or the AD group.
The different study outcome could depend on study
populations or the assay format. Unlike the previous re-
ports [18, 19], we measured absolute sTREM2 concen-
trations in the CSF samples. In the previous dementia
study [18], in which CSF TREM2 was found to be re-
duced in AD, the AD patients were approximately a dec-
ade older than the controls. This is similar to the
Swedish cohort in our report, but in contrast to the Nor-
wegian cohort which was well matched for age. Age-
matching thus does not seem to explain the differences
in study outcome, since we found a positive correlation
between sTREM2 levels and age.
The role of TREM2 in AD pathology is only partly
clear. TREM2 may have a neuroprotective function by
regulating microglial/macrophage polarization [38] and
serving as a phagocytic receptor [18, 39, 40]. TREM2
could thus serve to clear soluble Aβ-aggregates and
other toxic debris, and control the inflammatory reac-
tions elicited by the early AD pathology. However, the
effects of TREM2 deficiency on amyloid plaque load in
AβPP transgenic mice are inconsistent [41–43]. We
therefore compared the levels of sTREM2 with the AD
neuropathological markers CSF Aβ42, T-tau and P-tau.
Interestingly we found a positive correlation between
CSF sTREM2 and T-tau, P-tau and Aβ42 in the control
group. These correlations were not seen in the AD and
MCI groups. The signature of low CSF Aβ42 and high
CSF T-tau/P-tau is established and enables prodromal
AD diagnostics [44]. Several studies have found the neu-
rodegenerative markers T-tau and P-tau to increase
almost threefold from 40 to 90 years with healthy aging
[24, 45, 46]. Among aged subjects asymptomatic tauopa-
thy is being reported [47]. Correlation of CSF sTREM2
levels with T-tau/P-tau could thus be an indirect effect
of the age-dependent increase in T-tau/P-tau.
The positive correlation between sTREM2 and Aβ42
among controls is interesting because CSF Aβ42 is ultim-
ately reduced in association with amyloid deposition in AD.
CSF sTREM2 also correlated well with CSF measures of
Aβ38 and Aβ40, and the different Aβ measures correlated
well with each other. The increased CSF Aβ presumably
reflects altered Aβ metabolism, and not Aβ42-selective
changes associated with Aβ deposition. In a previous study
CSF Aβ42 did not correlate with age among the cognitively
healthy [24], while others reported a relation that best fit
curve models of increasing and culminating Aβ42 [48, 49]
and Aβ40 levels [49]. In the absence of amyloid deposits,
an increased CSF-Aβ peptide level probably reflects an
imbalance between production and clearance of Aβ. There
is evidence of decreased Aβ clearance in aged individuals
with sporadic AD [50]. Several mechanisms including age-
related changes to the vascular basement membrane and
impaired drainage along the lymphatic drainage pathway
are probably involved [51]. Amyloid formation depends on
seeding; that is, the local concentration of Aβ monomers
must reach a critical threshold in order for fibril formation
to begin [52]. Indeed, CSF Aβ42 was shown to transiently
increase by 20–30 % in three inbred AβPP-transgenic
models before it declined when amyloid plaques emerged
[53]. We speculate that the positive correlation between
CSF Aβ peptides and CSF sTREM2 among controls reflects
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a very early pre-symptomatic stage of dementia. These find-
ings are preliminary and need to be further examined in
other cohorts and in familial AD.
Conclusions
A new sensitive TREM2 ELISA was used to determine
CSF sTREM2 levels in cognitively healthy controls, and in
patients with AD and MCI. In the cognitively healthy, we
found CSF sTREM2 levels to increase with age, the most
important risk factor of AD. There was no statistically sig-
nificant difference in sTREM2 levels between diagnostic
states (healthy control, AD and MCI), but sTREM2 levels
correlated positively with the AD neuropathological CSF
biomarkers Aβ42 and T-tau and P-tau in controls. Age
should thus be considered when analysing sTREM2 in
CSF. We speculate that increased CSF sTREM2 levels
may reflect a very early microglial response to increased
soluble Aβ42 in pre-symptomatic AD brain.
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